Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 287,363 shares of the biopharmaceutical company’s stock after selling 10,600 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Gilead Sciences were worth $26,544,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Bellevue Group AG increased its position in shares of Gilead Sciences by 18.2% in the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after acquiring an additional 7,093 shares in the last quarter. Quantinno Capital Management LP increased its position in shares of Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after acquiring an additional 48,910 shares in the last quarter. McAdam LLC increased its position in shares of Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock worth $2,344,000 after acquiring an additional 3,627 shares in the last quarter. IRON Financial LLC acquired a new stake in shares of Gilead Sciences in the third quarter worth $830,000. Finally, Capital Investment Advisors LLC increased its position in shares of Gilead Sciences by 2.6% in the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after acquiring an additional 9,791 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.1 %

NASDAQ GILD opened at $109.95 on Friday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $111.03. The company has a 50-day simple moving average of $95.41 and a 200-day simple moving average of $88.73. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market capitalization of $137.03 billion, a PE ratio of 297.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s payout ratio is 832.43%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Royal Bank of Canada lifted their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Citigroup assumed coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 price target on the stock. Piper Sandler lifted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Truist Financial lifted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Finally, Robert W. Baird lifted their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $102.08.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total transaction of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 713,000 shares of company stock worth $67,945,181. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.